2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 268

The Effect of Renaming Gout to Urate Crystal Arthritis on Illness and Treatment Perceptions in Māori (the Indigenous People of Aotearoa/New Zealand)
Abstract Number: 269

Adverse Event Reporting Rates and Placebo/Standard-of-Care-Arm American College of Rheumatology Responses Vary By Region in Rheumatoid Arthritis Trials
Abstract Number: 270

Gaps in Knowledge about the Ontario Trillium Drug Program
Abstract Number: 271

Health Care Disparities for Infectious and Non-Infectious Uveitis in the US
Abstract Number: 272

Ethnic Disparities in Lupus Nephritis Outcomes in the Inland Empire: Findings from the Southern California Lupus Registry
Abstract Number: 273

Incidence of Systemic Lupus Erythematosus By Income: A Nationwide Study
Abstract Number: 274

Socioeconomic Disparities in Disease Activity in Patients with Rheumatoid Arthritis
Abstract Number: 275

Health Equity: Access to Rituximab for Patients Comparing Variable Access in a Single Rheumatology Clinic
Abstract Number: 276

Gender Differences in TNFi Treatment Adherence and Response in As Patients: A Prospective Longitudinal Cohort Study
Abstract Number: 277

Outcomes of Telemedicine for Rheumatoid Arthritis in the Alaska Native Population
Abstract Number: 278

The Effect of Patient, Prescriber and Region on the Initiation of First Biologic for Rheumatoid Arthritis: A Longitudinal Population Study
Abstract Number: 279

Variations and Disparities in Healthcare Teams Among Individuals with Lupus
Abstract Number: 280

Be Fierce. Take Control.TM an Evidence-Based Digital Lupus Awareness and Education Campaign for Young Minority Women at Risk for Lupus
Abstract Number: 281

Development of an African American Lupus Community-Based Patient and Provider Education Program: Lupus Conversations
Abstract Number: 282

The Utility of Positive ANA Referrals at the University of Chicago

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].